terminal complement component 5 inhibitors c5i eculizumab (Alexion Phrama)
86
Structured Review
Alexion Phrama
terminal complement component 5 inhibitors c5i eculizumab
Terminal Complement Component 5 Inhibitors C5i Eculizumab, supplied by Alexion Phrama, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+inhibitor+eculizumab/c5+inhibitors/pmc13055122-132-4-12
Average 86 stars, based on 1 article reviews
Terminal Complement Component 5 Inhibitors C5i Eculizumab, supplied by Alexion Phrama, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+inhibitor+eculizumab/c5+inhibitors/pmc13055122-132-4-12
Average 86 stars, based on 1 article reviews
terminal complement component 5 inhibitors c5i eculizumab - by Bioz Stars,
2026-09
86/100 stars
Images
1) Product Images from "Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry"
Article Title: Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry
Journal: American Journal of Hematology
doi: 10.1002/ajh.70268
Figure Legend Snippet: LDH ratio at specified time points in (A) eculizumab‐experienced patients and (B) C5i‐naive patients (with an LDH ratio of ≥ 1.5 × ULN). Baseline was defined as the date of ravulizumab treatment initiation. C5i, complement component 5 inhibitor; IQR, interquartile range; LDH, lactate dehydrogenase; ULN, upper limit of normal.
Techniques Used:
Figure Legend Snippet: RBC transfusion avoidance at specified time points in (A) eculizumab‐experienced patients and (B) C5i‐naive patients (with an LDH ratio of ≥ 1.5 × ULN) with complete data. Baseline was defined as the date of ravulizumab treatment initiation. C5i, complement component 5 inhibitor; LDH, lactate dehydrogenase; NA, not applicable; RBC, red blood cell; ULN, upper limit of normal.
Techniques Used:
Related Articles
Food & Beverages:Article Title: TMA in Kidney Transplantation Article Snippet: Thrombotic microangiopathy (TMA) is a rare and devastating complication of kidney transplantation, which often leads to graft failure.. Posttransplant TMA (PT-TMA) may occur either de novo or as a recurrence of the disease.. De novo TMA can be triggered by immunosuppressant drugs, antibody-mediated rejection, viral infections, and ischemia/reperfusion injury in patients with no evidence of the disease before transplantation. Blocking Assay:Article Title: TMA in Kidney Transplantation Article Snippet: Thrombotic microangiopathy (TMA) is a rare and devastating complication of kidney transplantation, which often leads to graft failure.. Posttransplant TMA (PT-TMA) may occur either de novo or as a recurrence of the disease.. De novo TMA can be triggered by immunosuppressant drugs, antibody-mediated rejection, viral infections, and ischemia/reperfusion injury in patients with no evidence of the disease before transplantation. Transplantation Assay:Article Title: Post-eculizumab meningococcaemia in vaccinated patients. Article Snippet: .. As no matched donors were identified for allogeneic stem cell transplantation (SCT), the patient was vaccinated with a conjugated vaccine against Neisseria meningitidis (Nimenrix, GSK), designed to prevent invasive meningococcal disease (IMD) by serogroups A,C,W135 and Y, followed two weeks later by initiation of PNH treatment with the Radial Immuno Diffusion:Article Title: Post-eculizumab meningococcaemia in vaccinated patients. Article Snippet: .. As no matched donors were identified for allogeneic stem cell transplantation (SCT), the patient was vaccinated with a conjugated vaccine against Neisseria meningitidis (Nimenrix, GSK), designed to prevent invasive meningococcal disease (IMD) by serogroups A,C,W135 and Y, followed two weeks later by initiation of PNH treatment with the other:Article Title: Defining the Complement Biomarker Profile of C3 Glomerulopathy Article Snippet: Second, the availability of a Article Title: Modifiers of complement activation for prevention of antibody-mediated injury to allografts Article Snippet: Current Opinion in Organ Transplantation 2011, 16:425–433 Purpose of review Improvements in prevention and management of cellular rejection of solid organ transplants, coupled with increasing numbers of sensitized patients, have focused attention on antibody-mediated rejection (AbMR).. Complement is a critical component of AbMR, in addition to interfacing between innate and adaptive immunity and the coagulation cascade.. This article reviews complement biology and strategies to overcome complement in AbMR, cognisant that antibody can act independently of complement. |